An evaluation of the interaction of pixantrone with formaldehyde-releasing drugs in cancer cells

• Published in: Cancer chemotherapy and pharmacology Vol. 89; no. 6; pp. 773 - 784
• Main Authors: Mansour, Oula C., Nudelman, Abraham, Rephaeli, Ada, Phillips, Don R., Cutts, Suzanne M., Evison, Benny J.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01-06-2022; Springer Nature B.V
• Subjects: Adducts; Antagonism; Anticancer properties; Apoptosis; Bioassays; Breast cancer; Cancer; Cancer Research; Cell death; Cell survival; Crosslinking; DNA Adducts; DNA damage; DNA topoisomerase (ATP-hydrolysing); DNA Topoisomerases, Type II - metabolism; Flow cytometry; Formaldehyde; Formaldehyde - pharmacology; Humans; In vitro methods and tests; Isoquinolines; Kinases; Lesions; Lymphoma; Medicine; Medicine & Public Health; Neoplasms; Non-Hodgkin's lymphoma; Oncology; Original Article; Pharmacology/Toxicology; Prodrugs; Prodrugs - pharmacology; Releasing; Scintillation counters; Synergism; DNA adduct; Mechanism of action; Formaldehyde; Topoisomerase II; Pixantrone
• ISSN: 0344-5704; 1432-0843
• DOI: 10.1007/s00280-022-04435-1

Purpose
Pixantrone is a synthetic aza-anthracenedione currently used in the treatment of non-Hodgkin’s lymphoma. The drug is firmly established as a poison of the nuclear enzyme topoisomerase II, however, pixantrone can also generate covalent drug-DNA adducts following activation by formaldehyde. While pixantrone-DNA adducts form proficiently in vitro, little evidence is presently at hand to indicate their existence within cells. The molecular nature of these lesions within cancer cells exposed to pixantrone and formaldehyde-releasing prodrugs was characterized along with the cellular responses to their formation.
Methods
In vitro crosslinking assays, [
14
C] scintillation counting analyses and alkaline comet assays were applied to characterize pixantrone-DNA adducts. Flow cytometry, cell growth inhibition and clonogenic assays were used to measure cancer cell kill and survival.
Results
Pixantrone-DNA adducts were not detectable in MCF-7 breast cancer cells exposed to [
14
C] pixantrone (10–40 µM) alone, however the addition of the formaldehyde-releasing prodrug AN9 yielded readily measurable levels of the lesion at ~ 1 adduct per 10 kb of genomic DNA. Co-administration with AN9 completely reversed topoisomerase II-associated DNA damage induction by pixantrone yet potentiated cell kill by the drug, suggesting that pixantrone-DNA adducts may promote a topoisomerase II-independent mechanism of cell death. Pixantrone-DNA adduct-forming treatments generally conferred mild synergism in multiple cell lines in various cell death and clonogenic assays, while pixantrone analogues either incapable or relatively defective in forming DNA adducts demonstrated antagonism when combined with AN9.
Conclusions
The features unique to pixantrone-DNA adducts may be leveraged to enhance cancer cell kill and may be used to guide the design of pixantrone analogues that generate adducts with more favorable anticancer properties.